OS02.6.A Lacosamide in monotherapy in brain tumour-related epilepsy (BTRE): results from an Italian multicentre retrospective study

Abstract Background Lacosamide (LCM) is a third-generation anti-seizure medication (ASM) approved for focal onset epilepsy in patients aged ≥4 years. Previous studies have reported an efficacy of LCM as add-on treatment brain tumour-related (BTRE). To date, there are no the literature focusing on lacosamide used monotherapy to treat BTRE. In our retrospective study we investigated and tolerability multicentre national cohort primary tumour patients. Patients Methods Adult who were treated with collected from 12 Italian Centres (either mainly involved neuro-oncology or epileptology). Main inclusion criteria diagnosis tumour; at least two focal-onset seizures disease course; either secondary after withdrawal previous ASMs. For each patient, evaluated seizure freedom 3 6 months (primary endpoints), side effects drop-out rate (secondary endpoints). Results We 132 The majority had diffuse gliomas, being those lower-grade glioma 66 (50.0%) glioblastoma 33 (25.0%). Overall, led seizure-freedom 64.4% 55% months. more ASMs before worse control than first choice.In 14 patients, observed despite progression magnetic resonance (MRI). Multivariate analysis showed that gross-total resection use steroids significantly associated higher Side mild (grade 1-2 according CTCAE classification), was low (1.5%). main dizziness somnolence. Conclusion This role has shown good half becoming seizure-free very drop-out. Further needed confirm these preliminary data prospective manner, adding quality life neurocognitive functions endpoints.